Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 6Solid Tumors 3Solid Tumor 3Mesothelioma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor, Adult 2Melanoma 2Cholangiocarcinoma 2Advanced Solid Tumors 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Esophageal Neoplasms 1DMMR Colorectal Cancer 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 4toripalimab 2tislelizumab 1spartalizumab 1sintilimab 1efineptakin alfa 1camrelizumab 1atezolizumab 1Taxes 1MK 2206 1Injections 1Cyclophosphamide 1Cetuximab 1Albumin-Bound Paclitaxel 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × spartalizumab × Other solid neoplasm × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡